These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 7318866)

  • 1. Estrogen-linked cytotoxic agents of potential value for the treatment of breast cancer.
    Leclercq G; Devleeschouwer N; Legros N; Heuson JC
    Eur J Cancer (1965); 1980; Suppl 1():287-93. PubMed ID: 7318866
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of steroids as carriers of cytotoxic agents in breast cancer: estrogens linked with nitrogen mustard groups [proceedings].
    Lippman M
    Cancer Treat Rep; 1978 Aug; 62(8):1259-60. PubMed ID: 688264
    [No Abstract]   [Full Text] [Related]  

  • 3. Aziridinylbenzoquinone (AZQ) in advanced breast cancer: a Cancer and Leukemia group B phase II trial.
    Budman DR; Forastiere A; Perloff M; Perry M; Aisner J; Weinberg V; Wood W
    Cancer Treat Rep; 1982 Oct; 66(10):1875-6. PubMed ID: 7127327
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II trials of the single agents baker's antifol, diaziquone, and epirubicin in advanced pancreatic cancer. Gastrointestinal Tumor Study Group.
    Cancer Treat Rep; 1987 Sep; 71(9):865-7. PubMed ID: 3476203
    [No Abstract]   [Full Text] [Related]  

  • 5. [Results of the clinical study of a preparation of diiodobenzotef in malignant tumors].
    Karev NI; Garin AM; Blokhina NG; Pershin MP; Trapeznikova MF
    Klin Med (Mosk); 1975 May; 52(5):50-3. PubMed ID: 1133992
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of an homo-aza-steroidal ester on estrogen receptor.
    Leclercq G; Devleeschouwer N; Pairas G; Camoutsis C; Catsoulacos P
    Methods Find Exp Clin Pharmacol; 1983; 5(6):365-7. PubMed ID: 6621181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
    Hoffmann J; Sommer A
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy of cancer of the lung.
    Shahid M
    J Med Liban; 1966; 19(6):321-30. PubMed ID: 5979355
    [No Abstract]   [Full Text] [Related]  

  • 9. Dietary genistein results in larger MNU-induced, estrogen-dependent mammary tumors following ovariectomy of Sprague-Dawley rats.
    Allred CD; Allred KF; Ju YH; Clausen LM; Doerge DR; Schantz SL; Korol DL; Wallig MA; Helferich WG
    Carcinogenesis; 2004 Feb; 25(2):211-8. PubMed ID: 14578162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological evaluation of doxorubicin-formaldehyde conjugates targeted to breast cancer cells.
    Burke PJ; Koch TH
    J Med Chem; 2004 Feb; 47(5):1193-206. PubMed ID: 14971899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphism of estrogen receptors in human breast cancer.
    Wittliff JL; Feldhoff PW; Fuchs A; Wiehle RD
    Prog Clin Biol Res; 1981; 74():375-96. PubMed ID: 6275406
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
    Bajo AM; Schally AV; Halmos G; Nagy A
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3742-8. PubMed ID: 14506166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Steroid receptors and endocrine control of breast tumors].
    Rochefort H
    Pathol Biol (Paris); 1977 Nov; 25(9):595-7. PubMed ID: 341047
    [No Abstract]   [Full Text] [Related]  

  • 14. Steroid hormone receptors in mammary carcinoma: the effect of tamoxifen.
    Koenders AJ; Beex LV; Geurts-Moespot J; Benraad TJ
    Eur J Cancer (1965); 1980; Suppl 1():63-6. PubMed ID: 7318871
    [No Abstract]   [Full Text] [Related]  

  • 15. Structure-activity correlations of anticancer agents: diaminopyrimidines, N-acyltriamines, bis-(1-aziridinyl)-phosphinyl carbamates, and aromatic nitrogen mustards.
    Lien EJ; Tong GL
    Cancer Chemother Rep; 1973; 57(3):251-61. PubMed ID: 4796118
    [No Abstract]   [Full Text] [Related]  

  • 16. [Results of experimental and clinical studies of a new antileukemic drug: hexaphosphamide. Review of the literature and the author's own results].
    Khomchenovskii EI
    Haematologia (Budap); 1977; 11(1-2):115-26. PubMed ID: 352850
    [No Abstract]   [Full Text] [Related]  

  • 17. [Status of plasma blood clotting factors during different stages of erythromyelosis in rats and the effect of hexaphosphamide on the indices studied].
    Stepanian MA; Chilingarian AG; Muradian LB
    Zh Eksp Klin Med; 1978; 18(2):24-8. PubMed ID: 278414
    [No Abstract]   [Full Text] [Related]  

  • 18. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
    Chatzistamou L; Schally AV; Nagy A; Armatis P; Szepeshazi K; Halmos G
    Clin Cancer Res; 2000 Oct; 6(10):4158-65. PubMed ID: 11051271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells.
    Tyagi AK; Agarwal C; Chan DC; Agarwal R
    Oncol Rep; 2004 Feb; 11(2):493-9. PubMed ID: 14719089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study of Estracyt in advanced breast cancer.
    Dawes PJ
    Cancer Treat Rep; 1982 Mar; 66(3):581-2. PubMed ID: 7060046
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.